Quantcast
Featuring Demian Dressler, DVM and Susan Ettinger, DVM, Dip. ACVIM (Oncology), authors of The Dog Cancer Survival Guide

Apigenin

Updated: October 1st, 2018

There were many studies, articles and books Dr. Dressler and Dr. Ettinger used when writing The Dog Cancer Survival Guide. Here is a list of the most important references about the use of apigenin.

Please note that in vivo and clinical use citations were included whenever possible. We have also included links to the papers, where available. Most of the papers are found on the National Institute of Health’s online library, PubMed.

Antigenotoxic effect of apigenin against anti-cancerous drugs. Siddique YH, Beg T, Afzal M. Toxicol In Vitro. 2008 Apr;22(3):625-31.

5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Choi EJ and Kim GH. Oncol Rep. 2009 Dec;22(6):1533-7.

The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Strouch MJ, et al. Pancreas. 2009 May;38(4):409-15.

Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Lee SH, et al. Cancer Lett. 2008 Jan 18;259(1):39-49.

Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Caltagirone S, et al. Int J Cancer. 2000 Aug 15;87(4):595-600.

Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Zhang S, Yang X, Morris ME. Molecular Pharmacology May 2004 vol. 65 no. 5 1208-1216

The chemopreventive flavonoid apigenin confers radiosensitizing effect in human tumor cells grown as monolayers and spheroids. Watanabe N, Hirayama R, Kubota N. J Radiat Res (Tokyo). 2007 Jan;48(1):45-50.

Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Shukla S and Gupta S. Mol Cancer Ther. 2006 Apr;5(4):843-52.

Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Gradolatto A, et al. Drug Metab Dispos. 2005 Jan;33(1):49-54.

Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. Shukla S, et al. FASEB J. 2005 Dec;19(14):2042-4.

Dietary apigenin suppresses IgE and inflammatory cytokines production in C57BL/6N mice. Yano S, et al. J Agric Food Chem. 2006 Jul 12;54(14):5203-7.

Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. Rezai-Zadeh K, et al. J Neuroinflammation. 2008; 5: 41.

Bioavailability of apigenin from apiin-rich parsley in humans. Meyer H, et al. Ann Nutr Metab. 2006;50(3):167-72.

Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Chen D, et al. Breast Cancer Res. 2007; 9(6): R80.

Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Chen D, et al. Biochem Pharmacol. 2005 May 15;69(10):1421-32.

Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells. Morrissey C, et al. Prostate. 2005 May 1;63(2):131-42.

Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Shukla S and Gupta S. Free Radic Biol Med. 2008 May 15;44(10):1833-45.

Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Torkin R, et al. Mol Cancer Ther. 2005 Jan;4(1):1-11.

Individual and interactive effects of apigenin analogs on G2/M cell-cycle arrest in human colon carcinoma cell lines. Wang W, et al. Nutr Cancer. 2004;48(1):106-14.

Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Torkin R, et al. Mol Cancer Ther. 2005 Jan;4(1):1-11.

Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Zheng PW, Chiang LC, Lin CC. Life Sci. 2005 Feb 4;76(12):1367-79.

Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Shukla S and Gupta S. Clin Cancer Res. 2004 May 1;10(9):3169-78.

Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Wang W, et al. Mol Carcinog. 2000 Jun;28(2):102-10.

Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Shukla S and Gupta S. Clin Cancer Res. 2004 May 1;10(9):3169-78.

Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. Llorens F, et al. Exp Cell Res. 2004 Sep 10;299(1):15-26.

Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. Constantinou A, et al. J Nat Prod. 1995 Feb;58(2):217-25.

Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Gupta S, Afaq F, Mukhtar H. Oncogene. 2002 May 23;21(23):3727-38.

Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. Brusselmans K, et al. J Biol Chem. 2005 Feb 18;280(7):5636-45.

Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Wang IK, Lin-Shiau SY, Lin JK. Eur J Cancer. 1999 Oct;35(10):1517-25.

Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Liang YC, et al. Carcinogenesis. 1999 Oct;20(10):1945-52.

Possible controversy over dietary polyphenols: benefits vs risks. Lambert JD, Sang S, Yang CS. Chem Res Toxicol. 2007 Apr;20(4):583-5.

Discover the Full Spectrum Approach to Dog Cancer